Exelixis (EXEL) Cash from Operations Growth (5y) (2015 - 2026)
Exelixis (EXEL) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn |
| 10 | Exelixis | 14.53 Bn | 13.76 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 44.81% |
| Jan 2, 2026 | 32.51% |
| Apr 4, 2025 | 30.40% |
| Sep 27, 2024 | 29.12% |
| Jun 28, 2024 | -1.92% |
| Mar 29, 2024 | -15.69% |
| Dec 29, 2023 | -36.77% |
| Sep 29, 2023 | -6.57% |
| Jun 30, 2023 | 10.19% |
| Mar 31, 2023 | 3.29% |
| Dec 30, 2022 | 6.67% |
| Sep 30, 2022 | 23.79% |
| Jul 1, 2022 | 41.26% |
| Apr 1, 2022 | 16.49% |
| Dec 31, 2021 | -21.16% |
| Oct 1, 2021 | 74.99% |
| Jul 2, 2021 | 55.37% |
| Apr 2, 2021 | -24.08% |
| Apr 3, 2020 | 26.53% |
| Sep 27, 2019 | 27.00% |